Tirzepatide's side effects scale with two things you can see on a calendar: how recently your dose went up, and how high it has gone. The Zepbound prescribing information breaks its adverse reaction data out by dose, which makes it more useful than a single list.
| Reaction | Placebo | 5 mg | 10 mg | 15 mg |
|---|---|---|---|---|
| Nausea | 8% | 25% | 29% | 28% |
| Diarrhea | 8% | 19% | 21% | 23% |
| Vomiting | 2% | 8% | 11% | 13% |
| Constipation | 5% | 17% | 14% | 11% |
| Abdominal pain | 5% | 9% | 9% | 10% |
| Dyspepsia | 4% | 9% | 9% | 10% |
| Injection site reactions | 2% | 6% | 8% | 8% |
| Fatigue | 3% | 5% | 6% | 7% |
| Hypersensitivity reactions | 3% | 5% | 5% | 5% |
| Hair loss | 1% | 5% | 4% | 5% |
| Belching | 1% | 4% | 5% | 5% |
| Reflux (GERD) | 2% | 4% | 4% | 5% |
| Dizziness | 2% | 4% | 5% | 4% |
How should you read this table?
Subtract the placebo column first. The label pools two trials, one in adults without diabetes and one in adults with type 2 diabetes, and people on placebo reported plenty of the same complaints. At 10 mg, nausea was 29% against 8% on placebo, so about 21 extra people per 100 had nausea because of the drug. Vomiting at 15 mg works out to about 11 extra per 100, and constipation at 5 mg to about 12 extra per 100.
The table lists reactions reported by at least 5% of any dose group. The label's full table goes down to 2%, and the warnings section covers rarer events that do not show up in a frequency table at all.
Do side effects get worse at higher tirzepatide doses?
Vomiting and diarrhea do: vomiting rises from 8% at 5 mg to 13% at 15 mg. Nausea plateaus around 28–29% at 10 and 15 mg. Constipation runs the other way, highest at 5 mg (17%) and lowest at 15 mg (11%).
Quitting tracks dose too. The label reports that 1.9%, 3.3% and 4.3% of people on 5, 10 and 15 mg stopped because of gastrointestinal reactions, against 0.5% on placebo. For any adverse reaction, discontinuation was 4.8%, 6.3% and 6.7% versus 3.4%. The SURMOUNT-1 paper (NEJM, 2022) reported 4.3%, 7.1% and 6.2% versus 2.6% for that single trial.
When in the schedule do they show up?
The label says the majority of nausea, vomiting and diarrhea events occurred during dose escalation and decreased over time. SURMOUNT-1 used a 20-week escalation period to reach 15 mg, and its authors describe gastrointestinal events as mostly mild to moderate and occurring primarily in that window.
| Stretch of treatment | What the label and trial point to | What to plan for |
|---|---|---|
| First 4 weeks at 2.5 mg | Start of escalation; birth control pills may work less well | Non-oral or backup contraception for 4 weeks |
| Each step up (every 4+ weeks) | Most nausea, vomiting and diarrhea reported here | Smaller meals, fluids; backup contraception again for 4 weeks |
| Stable maintenance dose | GI events decreased over time in trials | Report anything that persists or worsens |
| Any time | Rare pancreatitis, gallbladder disease, kidney injury, allergic reactions | Know the warning signs below |
Why does birth control matter on tirzepatide?
This is a tirzepatide-specific point worth knowing before your first dose. Section 7.2 of the Zepbound label advises people using oral hormonal contraceptives to switch to a non-oral method, or add a barrier method, for 4 weeks after starting Zepbound and for 4 weeks after each dose increase. The label connects this to delayed gastric emptying.
Which rare tirzepatide risks should you know?
These are uncommon in the trials, but they are the reasons to pick up the phone.
- Pancreatitis: adjudicated cases were 0.2% on Zepbound and 0.2% on placebo in the pooled trials; the label still lists it as a warning, including fatal forms seen with the drug class. Watch for persistent or severe abdominal pain, sometimes radiating to the back.
- Gallbladder disease: gallstones in 1.1% versus 1%, gallbladder inflammation in 0.7% versus 0.2%, and gallbladder removal in 0.2% versus none.
- Kidney injury: 0.5% versus 0.2%. Postmarketing reports include cases needing dialysis, mostly after vomiting or diarrhea caused dehydration.
- Serious allergy: 0.1% had severe hypersensitivity reactions versus none on placebo; postmarketing reports include anaphylaxis and angioedema.
- Low blood sugar with diabetes: in the type 2 diabetes trial, 4.2% versus 1.3%, and 10.3% when combined with a sulfonylurea.
The label also reports a mean heart rate increase of 1 to 3 beats per minute, and carries the boxed warning for thyroid C-cell tumors seen in rats. Neck lumps, hoarseness or trouble swallowing should be reported.
Is tirzepatide harder to tolerate than semaglutide?
The head-to-head SURMOUNT-5 trial (NEJM, 2025) does not settle it in its abstract: it reports that gastrointestinal events were the most common adverse events in both groups, mostly mild to moderate and primarily during dose escalation. Side-by-side label tables come from different trials and populations, so comparing them directly overstates the precision. Our semaglutide vs tirzepatide comparison covers efficacy.
Does any of this apply to compounded tirzepatide?
Not directly. These rates come from trials of branded Zepbound. Compounded tirzepatide is not FDA-approved and was never studied this way. FDA's page on unapproved GLP-1 drugs, current as of October 1, 2026, says it had received more than 730 adverse event reports for compounded tirzepatide as of May 31, 2026, with underreporting likely, and links some reports to dosing errors. Report problems to your prescriber and to FDA's MedWatch program.
For trial background, see SURMOUNT trial results; for medication interactions beyond birth control, GLP-1 drug interactions; and for the drug overview, tirzepatide.
Frequently asked questions
What is the most common side effect of tirzepatide?
Nausea. In the Zepbound label's pooled weight-reduction trials it affected 25% of people on 5 mg, 29% on 10 mg and 28% on 15 mg, compared with 8% on placebo. Diarrhea was next at 19% to 23%. The label says most of these events happened during dose escalation and eased over time.
How long does tirzepatide nausea last?
The label does not give a duration for individuals. It says the majority of nausea, vomiting and diarrhea events occurred during dose escalation and decreased over time, so each step up can bring a few rough days or weeks. If nausea stops you eating or drinking, contact your prescriber rather than waiting it out.
Does tirzepatide affect birth control pills?
Yes, according to section 7.2 of the Zepbound label. People taking oral hormonal contraceptives should switch to a non-oral method or add a barrier method for 4 weeks after starting and for 4 weeks after every dose increase. The label connects this to delayed gastric emptying, which can affect how oral medicines are absorbed.
Does tirzepatide cause hair loss?
The Zepbound label lists hair loss in 4% to 5% of people across the 5, 10 and 15 mg doses, compared with 1% on placebo. The label does not separate any direct drug effect from the effect of rapid weight loss. Mention new shedding to your prescriber, especially if it continues after your weight stabilizes.
Why do injection site reactions happen with tirzepatide?
The label reports injection site reactions in 6% to 8% of people on Zepbound versus 2% on placebo. They were more frequent in people who developed anti-tirzepatide antibodies, 11.3% versus 1%. Rotating sites is standard practice; redness that spreads, or swelling with hives or trouble breathing, is a different matter and needs prompt care.
Sources
- FDA label via DailyMed: Zepbound (tirzepatide) prescribing information — revised 8/2026; adverse reaction table, discontinuation, warnings, section 7.2 read 2026-11-08
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med 2022 — abstract read 2026-11-08 (PubMed record)
- Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med 2025;393:26-36 — abstract read 2026-11-08 (PubMed record)
- FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — content current as of 2026-10-01; adverse event counts read 2026-11-08